Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015672 (
fatigue
)
51,768
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neuromedin U
(
NMU
) is known to have potent actions on appetite and energy expenditure. Deletion of the
NMU
gene in mice leads to an obese phenotype, characterized by hyperphagia and
decreased energy
expenditure. Conversely, transgenic mice that overexpress proNMU exhibit reduced body weight and fat storage. Here, we show that central administration of
NMU
or the related peptide neuromedin S (NMS) dose-dependently decreases food intake, increases metabolic rate, and leads to significant weight loss in mice. The effects of
NMU
and NMS on both feeding and metabolism are almost completely lost in mice lacking the putative CNS receptor for
NMU
and NMS, NMUr2. However, NMUr2 knockout mice do not exhibit overt differences in body weight or energy expenditure compared with wild-type mice, suggesting that the dramatic phenotype of the
NMU
gene knockout mouse is not due simply to the loss of
NMU
/NMUr2 signaling. Putative proteolytic cleavage sites indicate that an additional peptide is produced from the
NMU
precursor protein, which is extremely well conserved between human, mouse, and rat. Here, we demonstrate that this peptide, proNMU(104-136), has a pronounced effect on energy balance in mice. Specifically, central administration of proNMU(104-136) causes a significant but transient ( approximately 4 h) increase in feeding, yet both food intake and body weight are decreased over the following 24 h. proNMU(104-136) administration also significantly increased metabolic rate. These results suggest that proNMU(104-136) is a novel modulator of energy balance and may contribute to the phenotype exhibited by
NMU
knockout mice.
...
PMID:Appetite-modifying actions of pro-neuromedin U-derived peptides. 1953 38